Clinical Trial Update: Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection Fraction [Phase 3]

View source ↗

Summary

Phase 3 open-label trial evaluating safety and tolerability of LCZ696 (sacubitril/valsartan) in patients with heart failure with reduced ejection fraction.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Reduced Ejection Fraction

Drugs mentioned

• Entresto (sacubitril/valsartan)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Heart Failure With Reduced Ejection Fraction | Phase 3 | Status: COMPLETED | Results posted: 2019-02-20